PF-Atlas › Clinical Trials › NCT05657184
Treatment of Idiopathic Pulmonary Fibrosis by REGEND001
REGEND001 · Phase 1
Registry ID
NCT05657184
Phase
Phase 1
Status
Completed
Drug / intervention
REGEND001
Sponsor
Regend Therapeutics
Start
2021-07-19
Enrollment
12
Locations
3
About this trial
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05657184 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.